Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of naringenin nano inhalant in treating acute lung injury

An inhalant and naringenin technology, which is applied in the field of pharmacy, can solve the problems of limited dosage, single route of administration, and poor therapeutic effect, and achieve the goal of solving technical limitations, treating acute lung injury, and inhaling therapeutic effect. Effect

Inactive Publication Date: 2017-12-01
SHANGHAI YANGPU CENT HOSPITAL
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] The object of the present invention is to: overcome the deficiencies in the prior art, solve acute lung injury clinical administration route is single (mainly oral and intravenous administration), drug distribution reaches lung medicine amount is limited, therapeutic effect is not good, the course of disease The time is long, and the technical problem of acute lung injury cannot be fundamentally treated, and a kind of application of naringenin nano-inhalation agent in the treatment of acute lung injury is provided

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of naringenin nano inhalant in treating acute lung injury
  • Application of naringenin nano inhalant in treating acute lung injury
  • Application of naringenin nano inhalant in treating acute lung injury

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0047] Embodiment 1. Naringenin phospholipid complex

[0048] Take 50 mg of naringenin and 138 mg of dipalmitoyl lecithin and dissolve them together in an appropriate amount of ethanol solvent, sonicate to form a clear solution, and then rotary evaporate in a water bath at 35°C to remove the ethanol solvent to obtain the naringenin-phospholipid complex. The particle size measurement results showed that most of the particles were below 100nm. The distribution of naringenin-phospholipid complexes was observed under a transmission electron microscope, and most of them were spherical ( figure 1 ). The particle size peak value of the naringenin-phospholipid complex measured by a Malvern laser particle size analyzer is 86.82nm ( figure 2 ), PDI is 0.243, and the particle size range is concentrated between 60-90nm.

Embodiment 2

[0049] Embodiment 2. Naringenin solid lipid nanoparticles

[0050] Take 0.1g of naringenin, 2.0g of cetyl palmitate, and 0.4g of caprylic / capric glycerides, heat them in a water bath at 53°C until they melt, and mix them with 1.0g of naringenin as the oil phase. Phospholipid 1.5g, polyoxyethylene 660-12 hydroxystearate 1.8g, add water for injection 100mL, stir and dissolve, heat to 53°C, as the water phase; under the condition of stirring and nitrogen, add the water phase dropwise to the same temperature In the oil phase of the mixture, continue to stir for a certain period of time to form colostrum, ultrasonically probe for 5 minutes, stir at 0-2°C for 2 hours, and filter through 0.22 μm micropores to obtain naringenin solid lipid nanoparticles. Observed under a scanning transmission electron microscope, most of them are particles below 100 nanometers.

Embodiment 3

[0051] Embodiment 3. Naringenin liposomes

[0052] Take 100mg of naringenin, 320mg of soybean lecithin, and 30mg of cholesterol in an eggplant-shaped flask, add 5ml of tetrahydrofuran to dissolve completely, and then evaporate in a water bath at 35°C to remove the organic solvent, and form a thin uniform film on the inner wall of the eggplant-shaped flask; Add 200ml of pH 5.0 phosphate buffer solution with 2.26g of lactose into an eggplant-shaped flask, place it at 37°C and shake at a constant temperature of 100 rpm for 1 hour to fully hydrate it, take it out and ultrasonically disperse it for 10 minutes to obtain naringenin lipid plastid.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides application of a naringenin nano inhalant in treating acute lung injury, and relates to the field of pharmaceutics. Naringenin is adopted as a treatment medicine, the naringenin nano inhalant targeting to lung macrophage is prepared, and application of the naringenin nano inhalant in treating acute lung injury is provided. Results of in-vivo pharmacodynamic tests show that the naringenin nano inhalant provided by the invention is remarkable in inhalation treatment effect, the technical limit of single clinical administration ways (mainly including oral taking and intravenous administration) is very well solved, and acute lung injury is fundamentally treated; in addition, when a relatively small dosage of the naringenin nano inhalant provided by the invention is used, a very good anti-inflammation function is achieved, meanwhile a carrier material of the naringenin nano inhalant is identical to surface active substances in a lung, and thus the medicine can be smoothly conveyed to affected focuses.

Description

technical field [0001] The invention relates to the field of pharmacy, in particular to the application of a naringenin nano-inhalation agent in the treatment of acute lung injury. Background technique [0002] Acute lung injury is caused by a variety of non-cardiogenic severe intrapulmonary and extrapulmonary infections; and the onset of acute lung injury is rapid, often causing damage to alveolar epithelial cells and capillary endothelial cells, resulting in diffuse pulmonary interstitial and alveolar edema , leading to acute hypoxic respiratory insufficiency and even death. At present, the clinical treatment of acute lung injury mainly focuses on actively treating the primary disease, controlling infection, and improving ventilation and tissue support. The treatment methods that have been adopted at home and abroad to reduce the inflammatory response of the lungs are as follows: [0003] (1) Oral non-steroidal anti-inflammatory drugs: These drugs mainly inhibit the synt...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/72A61K31/352A61P11/00
CPCA61K9/007A61K31/352
Inventor 朱李飞余自成林艳袁杰
Owner SHANGHAI YANGPU CENT HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com